Fierce Pharma Asia—Enhertu's HER2-low breast cancer win; Takeda's $2B gene therapy pact; Xtandi march-in campaign

AstraZeneca and Daiichi Sankyo's Enhertu posted a first-in-class win in HER2-low breast cancer. Takeda signed a deal worth up to $2 billion to develop non-viral gene therapies. U.S. lawmakers lent support to a march-in petition asking the government to sidestep patents protecting Astellas and Pfizer's Xtandi. And more.

Related Keywords

Japan ,China ,Tokyo ,Canada ,Japanese ,Canadian ,Naoya Miura ,Daiichi Sankyo Enhertu ,Glaxosmithkline ,Human Services ,University Of Iowa ,China Northwestaf University ,Pfizer ,Astrazeneca ,Department Of Health ,Tokyo University Of Science ,Daiichi Sankyo ,Bayh Dole Act ,Mitsubishi Tanabe ,Arch Venture Partners ,Tokyo University ,Enhertu ,Makeda ,Xtandi ,Astellas ,Medicago ,Mitsubishi Tanabe Pharma ,Fierce Pharma Asia ,Breast Cancer ,Ther2 ,Gene Therapy ,Patent Infringement ,Drug Prices ,Covid 19 ,Vaccine Development ,Rug Delivery Nanoparticle ,Anoparticles ,Obesity ,Pharma ,